The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment. Inavolisib in combination with ...

Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...